Real-World Treatment Patterns, Adherence and Healthcare Resource Utilization for Chronic Lymphocytic Leukemia/Small Lymphocytic Leukemia Among Veterans in the United States

被引：4
|
作者：
Yang, Keri [1 ]
Liu, Sizhu [1 ]
Tang, Boxiong [1 ]
Chanan-Khan, Asher [2 ]
机构：
[1] BeiGene Ltd, Emeryville, CA USA
[2] Mayo Clin, Jacksonville, FL USA
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148716
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4079
引用
收藏
页数：4
相关论文
共 50 条
  • [31] Real-World Health Care Utilization and Costs Among Patients Newly Initiating Systemic Therapy for Chronic Lymphocytic Leukemia (CLL) in the United States
    Matasar, Matthew J.
    Byfield, Stacey Dacosta
    Blauer-Peterson, Cori
    Montez, Melissa
    Reyes, Carolina
    Masaquel, Anthony
    BLOOD, 2016, 128 (22)
  • [32] Process mining for exploring treatment patterns in chronic lymphocytic leukemia in a real-world oncology database
    Black, James A.
    Castro, Felipe
    Lundberg, Linda
    Marino, Michael
    Niks, Rudi
    Rozinat, Anne
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2018, 27 : 66 - 66
  • [33] REAL WORLD TREATMENT PATTERNS IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS IN THE UNITED STATES - RITUXIMAB, THE MOST COMMONLY USED AGENT
    Brown, J.
    Shreay, S.
    Rai, K.
    VALUE IN HEALTH, 2014, 17 (03) : A235 - A235
  • [34] Healthcare Utilization and Comorbidity in Chronic Lymphocytic Leukemia
    Rotbain, Emelie C.
    Rostgaard, Klaus
    Andersen, Michael A.
    Da Cunha-Bang, Caspar
    Niemann, Carsten U.
    Frederiksen, Henrik
    Hjalgrim, Henrik
    CLINICAL EPIDEMIOLOGY, 2021, 13 : 1155 - 1165
  • [35] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Muluneh, Benyam
    Coombs, Catherine
    Drawdy, Lauren
    Kline, Theresa
    Deal, Allison
    Zhu, Anqi
    Miller, Jordan
    Sketch, Margo
    LEUKEMIA & LYMPHOMA, 2020, 61 : 119 - 119
  • [36] Impact of adherence to ibrutinib on clinical outcomes in real-world patients with chronic lymphocytic leukemia
    Collins, James
    Stump, Sarah E.
    Heiling, Hillary
    Muir, Michele
    Deal, Allison
    Proco, Darrian
    Nguyen, Catharine
    Cozad, Monica
    Mato, Anthony
    Coombs, Catherine C.
    Muluneh, Benyam
    LEUKEMIA & LYMPHOMA, 2022, 63 (08) : 1823 - 1830
  • [37] Real-World Evidence on Shift in Treatment Practice and Adoption of Novel Agents for Patients with Chronic Lymphocytic Leukemia in the United States
    Chanan-Khan, Asher
    Yang, Keri
    Liu, Sizhu
    Zimmerman, Todd
    Tang, Boxiong
    Ailawadhi, Sikander
    BLOOD, 2021, 138
  • [38] Healthcare Resource Utilization and Costs of Relapsed or Refractory Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Treated with Ibrutinib
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    De Nigris, Enrico
    Sarpong, Eric
    Farooqui, Mohammed Z. H.
    Laliberte, Francois
    BLOOD, 2022, 140 : 10911 - 10912
  • [39] Healthcare resource utilization and costs of chronic lymphocytic leukemia/small lymphocytic lymphoma patients who relapse or are refractory to ibrutinib
    De Nigris, Enrico
    Yang, Xiaoqin
    Zanardo, Enrico
    Lejeune, Dominique
    Farooqui, Mohammed Z. H.
    Gandra, Shravanthi R.
    Laliberte, Francois
    FUTURE ONCOLOGY, 2024, 20 (35) : 2723 - 2735
  • [40] Real-world treatment patterns, adherence, costs, and healthcare resource utilization associated with Waldenstrom macroglobulinemia in the United States.
    Yang, Keri
    Castillo, Jorge J.
    Ratiu, Anna
    Delinger, Rachel
    Zimmerman, Todd
    Tang, Boxiong
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
12345